Cargando…

Serum Col3-4: A new type III and IV collagen biochemical marker of synovial tissue turnover in patients with rheumatoid arthritis

The objective of this study was to develop a serum biochemical marker of the degradation of type III and IV collagens, as an index of synovium turnover, and evaluate its performance in patients with rheumatoid arthritis (RA). An enzyme-linked immunosorbent assay for serum synovial collagen fragments...

Descripción completa

Detalles Bibliográficos
Autores principales: Gineyts, Evelyne, Millet, Marjorie, Borel, Olivier, Coutant, Frédéric, Rousseau, Jean-Charles, Chapurlat, Roland, Marotte, Hubert, Garnero, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101524/
https://www.ncbi.nlm.nih.gov/pubmed/37053217
http://dx.doi.org/10.1371/journal.pone.0282954
_version_ 1785025538123890688
author Gineyts, Evelyne
Millet, Marjorie
Borel, Olivier
Coutant, Frédéric
Rousseau, Jean-Charles
Chapurlat, Roland
Marotte, Hubert
Garnero, Patrick
author_facet Gineyts, Evelyne
Millet, Marjorie
Borel, Olivier
Coutant, Frédéric
Rousseau, Jean-Charles
Chapurlat, Roland
Marotte, Hubert
Garnero, Patrick
author_sort Gineyts, Evelyne
collection PubMed
description The objective of this study was to develop a serum biochemical marker of the degradation of type III and IV collagens, as an index of synovium turnover, and evaluate its performance in patients with rheumatoid arthritis (RA). An enzyme-linked immunosorbent assay for serum synovial collagen fragments (Col3-4) was developed using an antibody recognizing a specific sequence from human type III collagen, which shares 70% homology with type IV collagen. Immunohistochemistry was performed to localize Col3-4 and the matrix metalloprotease MMP-9 which is upregulated in RA synovial fibroblasts in the synovial tissue from a RA patient. Serum Col3-4 was measured in patients with RA (n = 66, 73% women, mean age 62 years, median disease activity score 28 with erythrocyte sedimentation rate (DAS28-ESR) 2.6) and in sex and age matched healthy controls (n = 70, 76% women, mean age 59 years). Col3-4 immunoassay demonstrated adequate analytical performances and recognized a circulating neoepitope resulting from the cleavage of type III and IV collagens. In RA synovium tissue, Col3-4 fragments were localized in the lining layer where destructive fibroblasts are present and around blood vessels rich in type IV collagen. MMP-9 colocalized with Col3-4 staining and efficiently released Col3-4 fragments from type III and type IV collagen digestion. Serum Col3-4 was markedly increased in patients with RA (+240% vs controls, p < 0.0001) and correlated with DAS28-ESR (r = 0.53, p < 0.0001). Patients with RA and active disease (DAS28-ESR > 3.2, n = 20) had 896% (p < 0.0001) higher levels than subjects with low activity (n = 46). Serum Col3-4 is a specific and sensitive biochemical marker reflecting MMP- mediated type III and IV collagen degradation from synovial tissue. Serum Col3-4 levels are markedly increased in patients with RA, particularly in those with active disease, suggesting that it may be useful for the clinical investigation of RA.
format Online
Article
Text
id pubmed-10101524
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-101015242023-04-14 Serum Col3-4: A new type III and IV collagen biochemical marker of synovial tissue turnover in patients with rheumatoid arthritis Gineyts, Evelyne Millet, Marjorie Borel, Olivier Coutant, Frédéric Rousseau, Jean-Charles Chapurlat, Roland Marotte, Hubert Garnero, Patrick PLoS One Research Article The objective of this study was to develop a serum biochemical marker of the degradation of type III and IV collagens, as an index of synovium turnover, and evaluate its performance in patients with rheumatoid arthritis (RA). An enzyme-linked immunosorbent assay for serum synovial collagen fragments (Col3-4) was developed using an antibody recognizing a specific sequence from human type III collagen, which shares 70% homology with type IV collagen. Immunohistochemistry was performed to localize Col3-4 and the matrix metalloprotease MMP-9 which is upregulated in RA synovial fibroblasts in the synovial tissue from a RA patient. Serum Col3-4 was measured in patients with RA (n = 66, 73% women, mean age 62 years, median disease activity score 28 with erythrocyte sedimentation rate (DAS28-ESR) 2.6) and in sex and age matched healthy controls (n = 70, 76% women, mean age 59 years). Col3-4 immunoassay demonstrated adequate analytical performances and recognized a circulating neoepitope resulting from the cleavage of type III and IV collagens. In RA synovium tissue, Col3-4 fragments were localized in the lining layer where destructive fibroblasts are present and around blood vessels rich in type IV collagen. MMP-9 colocalized with Col3-4 staining and efficiently released Col3-4 fragments from type III and type IV collagen digestion. Serum Col3-4 was markedly increased in patients with RA (+240% vs controls, p < 0.0001) and correlated with DAS28-ESR (r = 0.53, p < 0.0001). Patients with RA and active disease (DAS28-ESR > 3.2, n = 20) had 896% (p < 0.0001) higher levels than subjects with low activity (n = 46). Serum Col3-4 is a specific and sensitive biochemical marker reflecting MMP- mediated type III and IV collagen degradation from synovial tissue. Serum Col3-4 levels are markedly increased in patients with RA, particularly in those with active disease, suggesting that it may be useful for the clinical investigation of RA. Public Library of Science 2023-04-13 /pmc/articles/PMC10101524/ /pubmed/37053217 http://dx.doi.org/10.1371/journal.pone.0282954 Text en © 2023 Gineyts et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Gineyts, Evelyne
Millet, Marjorie
Borel, Olivier
Coutant, Frédéric
Rousseau, Jean-Charles
Chapurlat, Roland
Marotte, Hubert
Garnero, Patrick
Serum Col3-4: A new type III and IV collagen biochemical marker of synovial tissue turnover in patients with rheumatoid arthritis
title Serum Col3-4: A new type III and IV collagen biochemical marker of synovial tissue turnover in patients with rheumatoid arthritis
title_full Serum Col3-4: A new type III and IV collagen biochemical marker of synovial tissue turnover in patients with rheumatoid arthritis
title_fullStr Serum Col3-4: A new type III and IV collagen biochemical marker of synovial tissue turnover in patients with rheumatoid arthritis
title_full_unstemmed Serum Col3-4: A new type III and IV collagen biochemical marker of synovial tissue turnover in patients with rheumatoid arthritis
title_short Serum Col3-4: A new type III and IV collagen biochemical marker of synovial tissue turnover in patients with rheumatoid arthritis
title_sort serum col3-4: a new type iii and iv collagen biochemical marker of synovial tissue turnover in patients with rheumatoid arthritis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101524/
https://www.ncbi.nlm.nih.gov/pubmed/37053217
http://dx.doi.org/10.1371/journal.pone.0282954
work_keys_str_mv AT gineytsevelyne serumcol34anewtypeiiiandivcollagenbiochemicalmarkerofsynovialtissueturnoverinpatientswithrheumatoidarthritis
AT milletmarjorie serumcol34anewtypeiiiandivcollagenbiochemicalmarkerofsynovialtissueturnoverinpatientswithrheumatoidarthritis
AT borelolivier serumcol34anewtypeiiiandivcollagenbiochemicalmarkerofsynovialtissueturnoverinpatientswithrheumatoidarthritis
AT coutantfrederic serumcol34anewtypeiiiandivcollagenbiochemicalmarkerofsynovialtissueturnoverinpatientswithrheumatoidarthritis
AT rousseaujeancharles serumcol34anewtypeiiiandivcollagenbiochemicalmarkerofsynovialtissueturnoverinpatientswithrheumatoidarthritis
AT chapurlatroland serumcol34anewtypeiiiandivcollagenbiochemicalmarkerofsynovialtissueturnoverinpatientswithrheumatoidarthritis
AT marottehubert serumcol34anewtypeiiiandivcollagenbiochemicalmarkerofsynovialtissueturnoverinpatientswithrheumatoidarthritis
AT garneropatrick serumcol34anewtypeiiiandivcollagenbiochemicalmarkerofsynovialtissueturnoverinpatientswithrheumatoidarthritis